Third Rock-backed Maze Therapeutics reveals profit in US IPO filing, ET HealthWorld
New Delhi: Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its paperwork for a U.S. initial public ...
